Fabio is a Global Consultant and Bio-tech Specialist with more than 15 years’ experience in cell and gene therapy. His exceptional ability to identify and evaluate new assets, products, services, and business models has positioned him as a trusted advisor to both large organizations and life science/biotech startups. With a keen strategic vision, he guides clients in overcoming hurdles, building value, and creating investable propositions. Founder of CharaBio, an innovative consulting firm, Fabio’s mission is to assist investors, Pharma, and biotech companies in understanding the dynamic cell and gene therapy market.
In 2019, he joined Claris Ventures, an €85M biotech-focused VC fund, supporting the team with equity investments in early-stage biopharma companies. In 2013, Fabio was invited to contribute his expertise to the Parenteral Drug Association (PDA) Cell and Gene Task Force (members include executives from GSK, Novartis, Lonza, Johnson & Johnson, Adaptimmune, Takeda, Bluebird Bio) that had been set up with the aim to write the Technical Report 81 about how to develop a manufacturing control strategy for cell and gene based medicinal products.
Fabio initiated his career at Sorin Group (now LivaNova), a medical device company, after earning a BSc and MSc with honors in Biomedical Engineering from the Polytechnic University of Turin (Italy). Subsequently, he moved to Newcastle (UK) for an Engineering Doctorate in Biopharmaceutical Process Development at Newcastle University.
He is also a Certified Lean Six Sigma Black Belt. Fabio is based in London (UK).
Veritux independent consultants are available where you need them – in all major markets and every global region.
